Deana Mohr (Haralampieva), CEO of MUVON Therapeutics AG, is leading the synchronization of efforts of cross-functional project teams to support timely milestone achievements, and to manage study issues and obstacles. After her PhD, she built up an international consortium and secured funding by Horizon2020 for the translation of the project from bench-to-bedside. Deana acted as a clinical project manager and coordinator and project leader at Wyss Zürich. Before that, Deana obtained her MSc in Cellular and Molecular Biology from the University of Constance, Germany (2011). Afterwards, she joined the Integrative Molecular Medicine program in Zurich as a PhD student and successfully graduated at the ETH in Radiopharmaceutical Sciences (2015). The results of her PhD thesis were the final step before the authorization of the muscle tissue-engineering project for clinical translation and motivated her to proceed with a further education in clinical trial management, regulatory affairs and various entrepreneurship programs, where she won various prestigious awards. In 2020 she co-founded MUVON Therapeutics AG and her mission is to bring the therapy to the ones in need.